**Core Concept**
CA 19-9 is a tumor marker that is predominantly associated with pancreatic adenocarcinoma, a type of cancer that originates in the pancreas. This marker is a mucin-type glycoprotein, and its levels are elevated in the blood of patients with pancreatic cancer.

**Why the Correct Answer is Right**
CA 19-9 is a specific tumor marker that is produced by the tumor cells of pancreatic adenocarcinoma. Elevated levels of CA 19-9 in the blood are often used as a diagnostic and monitoring tool for pancreatic cancer. The CA 19-9 antigen is recognized by the immune system, leading to the production of antibodies against it. These antibodies can be detected in the blood using various assays, providing a valuable tool for clinicians to monitor the progression of the disease.

**Why Each Wrong Option is Incorrect**
**Option A:** CA-125 is a tumor marker that is primarily associated with ovarian cancer, not pancreatic carcinoma. It is used to monitor the progression of ovarian cancer and to detect recurrence.
**Option B:** CA 27-29 is a tumor marker that is associated with breast cancer, particularly in patients with ductal carcinoma in situ (DCIS) and invasive breast cancer. It is not typically used for pancreatic cancer.
**Option D:** CA 15-3 is another tumor marker that is primarily associated with breast cancer, particularly in patients with metastatic breast cancer. It is not a specific marker for pancreatic carcinoma.

**Clinical Pearl / High-Yield Fact**
It is essential to note that CA 19-9 is not a specific marker for pancreatic cancer, as it can be elevated in other conditions such as chronic pancreatitis, bile duct obstruction, and other cancers. However, in the context of pancreatic adenocarcinoma, CA 19-9 is a valuable tool for diagnosis and monitoring.

**✓ Correct Answer: C. CA 19-9**